HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

44.420

-1.180-2.59%

Volume:1.94M

Turnover:86.59M

Market Cap:294.82B

PE:32.16

High:45.500

Open:45.500

Low:44.240

Close:45.600

52wk High:94.869

52wk Low:43.020

Shares:6.64B

HK Float Shares:258.00M

Volume Ratio:0.52

T/O Rate:0.75%

Dividend:0.23

Dividend Rate:0.53%

EPS(LYR):1.381

ROE:12.46%

ROA:7.02%

PB:3.91

PE(LYR):32.16

PS:8.04

Loading ...

Overview Company News Filings

HENGRUI PHARMA: GIC Private Limited Acquires Shares, Long Position Rises to 15.7%

Chinese Drug Regulator Accepts Hengrui Pharma's Drug Marketing Application for HRG2010 Capsules

MT Newswires Live

HENGRUI PHARMA's HRG2010 Capsule Marketing Application Accepted by NMPA

Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to HK$82.18 From HK$87.49, Keeps at Buy

MT Newswires Live

Hengrui Pharma's Half-Year Report: Heavy Spending Fails to Drive Growth as Former Sector Leader Struggles with Revenue Without Profit Expansion

Movement Alert｜HENGRUI PHARMA Falls 3.03% in Regular Trading, BOCOM International Cuts Target Price Citing Continued Pressure on Legacy Products

Hengrui Pharma's Growth Architecture Shifts: Second Growth Engine Accelerates as Global Valuation Framework Expands

Hengrui Pharma Gets Nod to Trial SHR-8203 Injection

MT Newswires Live

Hengrui Pharma Unit Gets China Nod for Lupus Drug Trial

MT Newswires Live

Movement Alert｜HENGRUI PHARMA Declines 3.18% in Regular Trading, Extending Sell-Off on Weak H1 Earnings Quality

Hengrui Pharmaceuticals Unit Gets China Marketing Nod for Paroxysmal Nocturnal Hemoglobinuria Drug

MT Newswires Live

Jiangsu Hengrui Pharmaceuticals- Nmpa Notice Approving Developed Class 1 Innovative Drug Licancopan Fumarate (Hrs-5965) Capsules for Marketing

THOMSON REUTERS

HENGRUI PHARMA (01276) Gets Clinical Trial Approval for SHR-7012 Injection Targeting Cutaneous Lupus Erythematosus

Jiangsu Hengrui Hong Kong Shares Hit Record Low on Quarterly Profit Miss

Movement Alert｜HENGRUI PHARMA Falls 8.55% in Regular Trading, H1 Revenue Declines as Core Profit Drops 12.7%

Hengrui Pharma Announces Resignation of Joint Company Secretary Liu Xiaohan

Bulletin Express

Hengrui Pharma Appoints Tian Fei as New Board Secretary

HENGRUI PHARMA Proposes New H-Share Incentive Scheme for 2026

Hengrui Pharma Maintains H1 2026 Profitability; Innovative Drug Sales Rise 16.4% Despite Flat Revenue

Bulletin Express

Hengrui Pharma Unveils 2026 A-Share Employee Stock Ownership Plan Valued at Approx. RMB 0.34 Billion

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/01276/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"HENGRUI PHARMA","latestPrice":44.42,"timestamp":1789632489005,"preClose":45.6,"halted":0,"volume":1936525,"delay":0,"changeRate":-0.025877192982456134,"floatShares":258000000,"shares":6637000000,"eps":1.3810181087782063,"marketStatus":"Closed","change":-1.18,"latestTime":"09-17 16:08:09","open":45.5,"high":45.5,"low":44.24,"amount":86589646,"amplitude":0.027632,"askPrice":44.46,"askSize":3400,"bidPrice":44.42,"bidSize":12600,"shortable":3,"etf":0,"ttmEps":1.3619296296645007,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789695000000},"marketStatusCode":5,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":45.6,"dividendRate":0.005253,"openAndCloseTimeList":[[1789608600000,1789617600000],[1789621200000,1789632000000]],"volumeRatio":0.518853,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.","latestPrice":43.23,"timestamp":1789628400000,"preClose":43.52,"halted":0,"volume":35252300,"delay":0,"premium":"-12.20"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":258000000,"roa":"7.02%","roe":"12.46%","lyrEps":1.381018,"volumeRatio":0.518853,"shares":6637000000,"dividePrice":0.234071,"high":45.5,"amplitude":0.027632,"preClose":45.6,"low":44.24,"week52Low":43.02,"pbRate":"3.91","psRate":"8.04","week52High":94.869,"institutionHeld":0,"latestPrice":44.42,"committee":0.575,"eps":1.3810181087782063,"divideRate":0.005269,"volume":1936525,"delay":0,"ttmEps":1.3619296296645007,"open":45.5,"prevYearClose":71.002,"prevWeekClose":43.76,"prevMonthClose":46.06,"prevQuarterClose":57.85,"fiveDayClose":43.96,"twentyDayClose":49.66,"sixtyDayClose":56.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[{"date":"2026-08-19","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787103000000,"name":null,"time":"","dateTimestamp":1787068800000,"actualEps":null},{"date":"2026-04-29","symbol":"01276","amount":0.22828,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2026-04-30","defaultRemindTime":1777426200000,"name":"恒瑞医药","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-27","payableDate":"2026-04-30","currency":"HKD","dateTimestamp":1777392000000,"payDate":"2026-05-27"},{"date":"2026-04-22","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1776821400000,"name":null,"time":"","dateTimestamp":1776787200000,"actualEps":null},{"date":"2026-03-26","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null},{"date":"2025-10-28","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761615000000,"name":null,"time":"","dateTimestamp":1761580800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[{"executeDate":"2026-04-29","recordDate":"2026-04-30","paymentDate":"2026-05-27","value":0.22828,"currency":"HKD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.5455,"hold":0.1818,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5455,"analysts":11,"updateTime":1786723200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2026-09-16","current":32.620895,"percent":0.01227,"low":36.382401,"twenty":43.825898,"median":51.677932,"eighty":56.983927,"high":65.582363,"avg":51.073535,"sd":7.480955,"marketCap":335564360039.49},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53},{"date":"2025-05-30","current":53.015805,"twenty":51.822085,"median":52.540895,"eighty":52.926837,"marketCap":395731540422.24},{"date":"2025-06-06","current":52.120101,"twenty":52.130014,"median":52.555929,"eighty":53.075252,"marketCap":390038198012.59},{"date":"2025-06-13","current":52.209491,"twenty":52.177631,"median":52.691227,"eighty":53.357137,"marketCap":390861633032.23},{"date":"2025-06-20","current":50.172412,"twenty":51.591196,"median":52.469796,"eighty":53.075252,"marketCap":374874997562.85},{"date":"2025-06-27","current":50.314776,"twenty":50.363569,"median":52.169666,"eighty":53.013533,"marketCap":376991477472.78},{"date":"2025-07-04","current":51.666141,"twenty":50.343584,"median":52.120101,"eighty":53.004446,"marketCap":387134991658.26},{"date":"2025-07-11","current":55.507007,"twenty":50.44351,"median":52.13337,"eighty":53.090114,"marketCap":415495681161.23},{"date":"2025-07-18","current":57.272274,"twenty":50.582121,"median":52.209491,"eighty":54.057606,"marketCap":428373566715.29},{"date":"2025-07-25","current":54.897923,"twenty":50.594414,"median":52.555929,"eighty":55.711415,"marketCap":412107620053.2},{"date":"2025-08-01","current":59.731878,"twenty":50.855059,"median":52.994419,"eighty":55.972407,"marketCap":445624526286.47},{"date":"2025-08-08","current":59.478715,"twenty":51.107295,"median":53.05296,"eighty":56.541585,"marketCap":444845815775.64},{"date":"2025-08-15","current":61.917611,"twenty":51.356483,"median":53.519848,"eighty":59.478715,"marketCap":462392609292.46},{"date":"2025-08-22","current":58.782188,"twenty":51.569512,"median":54.477764,"eighty":60.15932,"marketCap":470428104569.66},{"date":"2025-08-29","current":59.85298,"twenty":51.666141,"median":55.691374,"eighty":59.937003,"marketCap":481284287403.35},{"date":"2025-09-05","current":65.582363,"twenty":51.677932,"median":55.770266,"eighty":60.732448,"marketCap":526832269752.24},{"date":"2025-09-12","current":62.481332,"twenty":51.8337,"median":55.972407,"eighty":61.285609,"marketCap":502824785657.99},{"date":"2025-09-19","current":63.179889,"twenty":52.120101,"median":56.254853,"eighty":61.852995,"marketCap":508085671393.42},{"date":"2025-09-26","current":63.528382,"twenty":52.146639,"median":56.965096,"eighty":62.270337,"marketCap":509562668601.01},{"date":"2025-10-03","current":64.989073,"twenty":52.165061,"median":57.272274,"eighty":62.504861,"marketCap":522523002865.02},{"date":"2025-10-10","current":61.782766,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"marketCap":496019912951.91},{"date":"2025-10-17","current":58.903713,"twenty":52.323014,"median":59.170669,"eighty":62.619084,"marketCap":472537436949.31},{"date":"2025-10-24","current":59.187086,"twenty":52.484015,"median":59.039802,"eighty":62.52839,"marketCap":474983377696.11},{"date":"2025-10-31","current":57.072441,"twenty":52.552922,"median":59.021138,"eighty":62.417499,"marketCap":465758305542.93},{"date":"2025-11-07","current":54.713071,"twenty":52.619069,"median":58.881843,"eighty":62.304573,"marketCap":446224987036.64},{"date":"2025-11-14","current":55.883072,"twenty":52.812504,"median":58.231971,"eighty":62.27542,"marketCap":457058673340.29},{"date":"2025-11-21","current":52.805265,"twenty":52.880927,"median":57.030538,"eighty":62.209511,"marketCap":431684582485.14},{"date":"2025-11-28","current":55.237621,"twenty":52.99843,"median":56.630614,"eighty":62.069705,"marketCap":453209419829.34},{"date":"2025-12-05","current":54.841023,"twenty":53.00899,"median":56.437545,"eighty":61.965159,"marketCap":450729029423.46},{"date":"2025-12-12","current":56.212257,"twenty":53.045529,"median":56.385682,"eighty":61.891765,"marketCap":462853512587.19},{"date":"2025-12-19","current":54.083493,"twenty":53.045529,"median":56.227363,"eighty":61.831221,"marketCap":446374731108.34},{"date":"2025-12-24","current":54.414957,"twenty":53.090114,"median":56.103073,"eighty":61.798561,"marketCap":450509359276.9},{"date":"2026-01-02","current":53.078544,"twenty":53.065996,"median":55.972407,"eighty":61.785925,"marketCap":441174507319.22},{"date":"2026-01-09","current":56.743223,"twenty":53.0878,"median":56.0944,"eighty":61.695241,"marketCap":472808676524.34},{"date":"2026-01-16","current":55.187351,"twenty":53.304215,"median":56.103073,"eighty":61.405393,"marketCap":461338821289.95},{"date":"2026-01-23","current":52.546341,"twenty":53.0878,"median":56.076447,"eighty":61.296167,"marketCap":438839874056.97},{"date":"2026-01-30","current":51.677141,"twenty":52.994149,"median":55.908509,"eighty":61.278475,"marketCap":433553740508.2},{"date":"2026-02-06","current":50.918226,"twenty":52.680723,"median":55.839154,"eighty":61.101743,"marketCap":428270226283.58},{"date":"2026-02-13","current":51.771686,"twenty":52.512455,"median":55.711415,"eighty":60.890064,"marketCap":437949787160.49},{"date":"2026-02-20","current":51.752043,"twenty":52.351169,"median":55.691374,"eighty":60.824953,"marketCap":437153052005.04},{"date":"2026-02-27","current":50.215456,"twenty":52.151244,"median":55.507566,"eighty":60.720339,"marketCap":428825318404.97},{"date":"2026-03-06","current":49.335298,"twenty":51.80347,"median":55.280584,"eighty":60.654676,"marketCap":417912584744.19},{"date":"2026-03-13","current":48.90444,"twenty":51.75217,"median":55.201025,"eighty":60.572606,"marketCap":416170839186.33},{"date":"2026-03-20","current":48.948437,"twenty":51.671435,"median":55.086674,"eighty":60.515374,"marketCap":414967977646.95},{"date":"2026-03-27","current":47.483832,"twenty":51.400677,"median":54.94883,"eighty":60.443129,"marketCap":414588875872.42},{"date":"2026-04-02","current":49.302243,"twenty":51.107295,"median":54.905743,"eighty":60.227005,"marketCap":432534434303.11},{"date":"2026-04-10","current":49.055344,"twenty":50.995993,"median":54.897923,"eighty":60.186394,"marketCap":433687668394.36},{"date":"2026-04-17","current":48.417764,"twenty":50.589497,"median":54.65026,"eighty":60.143018,"marketCap":428230701835.75},{"date":"2026-04-24","current":45.835792,"twenty":50.342877,"median":54.475147,"eighty":60.015062,"marketCap":426879682872.04},{"date":"2026-04-30","current":44.026312,"twenty":50.285416,"median":54.355253,"eighty":59.903394,"marketCap":410132737659.64},{"date":"2026-05-08","current":43.161515,"twenty":50.207478,"median":54.262074,"eighty":59.804539,"marketCap":403472171949.3},{"date":"2026-05-15","current":44.128138,"twenty":49.985706,"median":54.115335,"eighty":59.70386,"marketCap":413593092820.6},{"date":"2026-05-22","current":41.244553,"twenty":49.583265,"median":53.983854,"eighty":59.631568,"marketCap":385683097978.4},{"date":"2026-05-29","current":40.98659,"twenty":49.34142,"median":53.840414,"eighty":59.564678,"marketCap":384603594259.51},{"date":"2026-06-05","current":38.394132,"twenty":49.063316,"median":53.633194,"eighty":59.459458,"marketCap":360799766229.36},{"date":"2026-06-12","current":39.515262,"twenty":48.81081,"median":53.517715,"eighty":59.36625,"marketCap":371084155232.86},{"date":"2026-06-18","current":39.444808,"twenty":48.417764,"median":53.467699,"eighty":59.301536,"marketCap":371311256576.18},{"date":"2026-06-26","current":39.60241,"twenty":47.951326,"median":53.090114,"eighty":59.187086,"marketCap":370974287810.31},{"date":"2026-07-03","current":44.319925,"twenty":47.638943,"median":53.015805,"eighty":59.069259,"marketCap":415476044901.86},{"date":"2026-07-10","current":45.319748,"twenty":47.348429,"median":52.993744,"eighty":59.024871,"marketCap":424327469311.14},{"date":"2026-07-17","current":43.189222,"twenty":46.151454,"median":52.805265,"eighty":58.96135,"marketCap":405818502739.33},{"date":"2026-07-24","current":43.433009,"twenty":45.632553,"median":52.604835,"eighty":58.912251,"marketCap":408200902707.63},{"date":"2026-07-31","current":43.935338,"twenty":45.29749,"median":52.543618,"eighty":58.877468,"marketCap":413706414238.87},{"date":"2026-08-07","current":44.394532,"twenty":45.008473,"median":52.339287,"eighty":58.813302,"marketCap":418841988303.56},{"date":"2026-08-14","current":42.6704,"twenty":44.628794,"median":52.189578,"eighty":58.452058,"marketCap":403085247281.44},{"date":"2026-08-21","current":40.686911,"twenty":44.408765,"median":52.120101,"eighty":57.75211,"marketCap":366558497066.13},{"date":"2026-08-28","current":40.334802,"twenty":44.24321,"median":51.814807,"eighty":57.336246,"marketCap":363468645736.13},{"date":"2026-09-04","current":39.220129,"twenty":44.050964,"median":51.771686,"eighty":57.152374,"marketCap":353565883607.49},{"date":"2026-09-11","current":36.382401,"twenty":43.912617,"median":51.717719,"eighty":57.022157,"marketCap":328426636361.34},{"date":"2026-09-16","current":37.134263,"twenty":43.825898,"median":51.677932,"eighty":56.983927,"marketCap":335564360039.49}],"updateTime":1789656651684},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1143746816","title":"HENGRUI PHARMA: GIC Private Limited Acquires Shares, Long Position Rises to 15.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143746816","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143746816?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:16","pubTimestamp":1787649406,"startTime":"0","endTime":"0","summary":"GIC Private Limited bought 3.66 million shares of HENGRUI PHARMA at an average of HKD 50.5655 per share on August 20, 2026, involving about HKD 185.00 million.Prior to the acquisition, GIC Private...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662678835","title":"Chinese Drug Regulator Accepts Hengrui Pharma's Drug Marketing Application for HRG2010 Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=2662678835","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662678835?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:43","pubTimestamp":1787625833,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) drug marketing authorization application for HRG2010 capsules, according to a Shanghai bourse filing on Tuesday.The drug is used for the treatment of Parkinson's disease.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","LU1023057109.AUD","LU0359201612.USD","LU0359202008.SGD","LU2543165471.USD","01276","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156894355","title":"HENGRUI PHARMA's HRG2010 Capsule Marketing Application Accepted by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1156894355","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156894355?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:24","pubTimestamp":1787581455,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA (01276) has announced that its marketing authorization application for the HRG2010 capsule has been formally accepted by China's National Medical Products Administration (NMPA),...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1580142542.USD","LU2488822045.USD","LU1255011170.USD","LU0359201612.USD","BK0196","LU2148510915.USD","LU1023057109.AUD","01276","LU2328871848.SGD","LU1820825898.SGD","LU1997244956.HKD","BK0239","BK0183","LU1997245094.SGD","LU2495084118.USD","LU1997245177.USD","LU2580892862.HKD","LU1064131003.USD","BK0188","LU2097828714.EUR","BK0012","LU1064130708.USD","LU1328615791.USD","LU2580892789.USD","LU2097828557.USD","LU0405327494.USD","BK0060","LU2097828631.EUR","LU2289578879.USD","LU0359202008.SGD","LU0359201885.HKD","LU1655091616.SGD","BK0028","BK1191","LU1146622755.USD","LU2097828805.USD","600276","LU1781817850.SGD","LU2543165471.USD","LU2097828474.EUR","LU1969619763.USD","IPOS","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661446273","title":"Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to HK$82.18 From HK$87.49, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2661446273","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661446273?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:13","pubTimestamp":1787570024,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals (HKG:1276) has an average rating of overweight and mean price target of HK$81.15, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and eco","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","LU0359201612.USD","LU2543165471.USD","LU0359201885.HKD","LU0359202008.SGD","01276","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125046383","title":"Hengrui Pharma's Half-Year Report: Heavy Spending Fails to Drive Growth as Former Sector Leader Struggles with Revenue Without Profit Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1125046383","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125046383?lang=en_us&edition=fundamental","pubTime":"2026-08-24 15:46","pubTimestamp":1787557589,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SH: 600276) unveiled its half-year financial report in August 2026, and the mid-year scorecard, which had generated considerable market anticipation, fell...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0405327494.USD","LU2097828805.USD","LU0359201612.USD","LU1255011170.USD","600276","LU0359202008.SGD","LU0405327148.USD","LU1023057109.AUD","LU1146622755.USD","BK1191","LU2580892862.HKD","BK0060","BK0239","LU2488822045.USD","LU1655091616.SGD","BK0028","LU1969619763.USD","LU1997244956.HKD","LU0359201885.HKD","BK0183","BK0012","BK0196","BK1574","LU2495084118.USD","LU1820825898.SGD","LU1064131003.USD","LU1328615791.USD","LU1997245094.SGD","LU2097828714.EUR","LU2097828557.USD","LU2289578879.USD","LU1997245177.USD","LU1781817850.SGD","LU2097828474.EUR","BK1515","09939","LU2097828631.EUR","LU2328871848.SGD","LU2580892789.USD","LU1580142542.USD","BK0188","LU2543165471.USD","LU2148510915.USD","BK1161","01276","159938","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102739299","title":"Movement Alert｜HENGRUI PHARMA Falls 3.03% in Regular Trading, BOCOM International Cuts Target Price Citing Continued Pressure on Legacy Products","url":"https://stock-news.laohu8.com/highlight/detail?id=1102739299","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102739299?lang=en_us&edition=fundamental","pubTime":"2026-08-24 10:41","pubTimestamp":1787539319,"startTime":"0","endTime":"0","summary":"On August 24, HENGRUI PHARMA fell 3.03% in regular trading, trading at HKD 46.74/share, with turnover of HKD 327 million. The decline was triggered by BOCOM International issuing a research note on...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BOCOM International Cuts Hengrui Pharma Target Price","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157060014","title":"Hengrui Pharma's Growth Architecture Shifts: Second Growth Engine Accelerates as Global Valuation Framework Expands","url":"https://stock-news.laohu8.com/highlight/detail?id=1157060014","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157060014?lang=en_us&edition=fundamental","pubTime":"2026-08-23 21:06","pubTimestamp":1787490393,"startTime":"0","endTime":"0","summary":"On August 19, Hengrui Pharma (01276) delivered a resilient first-half earnings report. During the period, the company recorded operating revenue of RMB 15.456 billion, with net profit attributable to...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023057109.AUD","LU1064130708.USD","LU2328871848.SGD","LU1064131003.USD","LU1997244956.HKD","LU2097828474.EUR","LU1328615791.USD","LU2289578879.USD","BK0188","LU2543165471.USD","01276","LU2495084118.USD","BK0060","BK0183","BK0028","LU0359202008.SGD","LU1655091616.SGD","LU1997245094.SGD","LU2097828805.USD","LU1580142542.USD","LU2097828631.EUR","LU2580892862.HKD","BK0196","BK0012","600276","LU2580892789.USD","LU2097828714.EUR","LU0359201612.USD","LU2488822045.USD","LU1820825898.SGD","BK0239","LU2148510915.USD","LU0359201885.HKD","LU0405327148.USD","LU1997245177.USD","LU2097828557.USD","LU1781817850.SGD","LU0405327494.USD","LU1146622755.USD","LU1255011170.USD","LU1969619763.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661212256","title":"Hengrui Pharma Gets Nod to Trial SHR-8203 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2661212256","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661212256?lang=en_us&edition=fundamental","pubTime":"2026-08-21 10:08","pubTimestamp":1787278105,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  received approval from China's National Medical Products Administration for the clinical trial of SHR-8203 injection, according to a Shanghai bourse filing on Friday.The drug will be tested as a monotherapy for advanced solid tumors.The Chinese pharmaceutical company's Shanghai shares dropped 3% during the morning trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01276","BK1191","LU0359201612.USD","LU0359201885.HKD","LU0359202008.SGD","LU1023057109.AUD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661256285","title":"Hengrui Pharma Unit Gets China Nod for Lupus Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2661256285","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661256285?lang=en_us&edition=fundamental","pubTime":"2026-08-21 10:05","pubTimestamp":1787277919,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  (SHA:600276) unit Guangdong Hengrui Medicine obtained approval from China's drug regulator to begin clinical trials for SHR-7012 injection.SHR-7012 targets cutaneous lupus erythematosus, according to a Thursday aftermarket filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01276","LU0359202008.SGD","LU0359201612.USD","LU1023057109.AUD","BK1191","LU2543165471.USD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175051703","title":"Movement Alert｜HENGRUI PHARMA Declines 3.18% in Regular Trading, Extending Sell-Off on Weak H1 Earnings Quality","url":"https://stock-news.laohu8.com/highlight/detail?id=1175051703","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175051703?lang=en_us&edition=fundamental","pubTime":"2026-08-21 09:42","pubTimestamp":1787276522,"startTime":"0","endTime":"0","summary":"On August 21, HENGRUI PHARMA declined 3.18% in regular trading, trading at 47.66 HKD/share with turnover of approximately 109 million HKD, extending the prior session's 8.55% selloff.The decline...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Hengrui Pharma Extends Decline on Weak Cash Flow and Core Profit","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660282560","title":"Hengrui Pharmaceuticals Unit Gets China Marketing Nod for Paroxysmal Nocturnal Hemoglobinuria Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2660282560","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660282560?lang=en_us&edition=fundamental","pubTime":"2026-08-20 20:48","pubTimestamp":1787230129,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  unit Chengdu Suncadia Medicine obtained marketing approval for its Licancopan Fumarate Capsules from China's National Medical Products Administration.The approved indication is for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria  who have not previously received complement inhibitor therapy, according to a Thursday bourse filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0359202008.SGD","LU1023057109.AUD","LU0359201885.HKD","01276","LU2543165471.USD","BK1191","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660285347","title":"Jiangsu Hengrui Pharmaceuticals- Nmpa Notice Approving Developed Class 1 Innovative Drug Licancopan Fumarate (Hrs-5965) Capsules for Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2660285347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660285347?lang=en_us&edition=fundamental","pubTime":"2026-08-20 18:31","pubTimestamp":1787221884,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nFWN44H0I8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2148510915.USD","LU2580892862.HKD","LU2543165471.USD","BK0196","BK0028","LU1781817850.SGD","LU2289578879.USD","LU1328615791.USD","BK0060","LU1146622755.USD","LU2328871848.SGD","LU2580892789.USD","LU1255011170.USD","LU0359201885.HKD","LU1064131003.USD","LU2097828714.EUR","LU1655091616.SGD","BK0239","LU2495084118.USD","LU1997245094.SGD","LU1997245177.USD","LU2488822045.USD","LU0405327148.USD","LU0359201612.USD","LU2097828557.USD","LU1023057109.AUD","LU2097828805.USD","BK1191","01276","LU2097828631.EUR","BK0012","600276","BK0188","LU0405327494.USD","LU2097828474.EUR","BK0183","LU1580142542.USD","LU1969619763.USD","LU1820825898.SGD","LU1997244956.HKD","LU1064130708.USD","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130698825","title":"HENGRUI PHARMA (01276) Gets Clinical Trial Approval for SHR-7012 Injection Targeting Cutaneous Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=1130698825","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130698825?lang=en_us&edition=fundamental","pubTime":"2026-08-20 18:26","pubTimestamp":1787221594,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA (01276) has announced that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2580892862.HKD","LU1023057109.AUD","LU2580892789.USD","LU1580142542.USD","BK1191","LU2328871848.SGD","LU1820825898.SGD","MDTX","LU1997245177.USD","LU0359202008.SGD","BK0183","LU1781817850.SGD","LU2488822045.USD","LU2148510915.USD","LU1655091616.SGD","IBBQ","LU0405327494.USD","BMED","LU1328615791.USD","LU1997245094.SGD","LU2097828714.EUR","PSYK","01276","LU2097828557.USD","600276","LU1997244956.HKD","BK0060","LU2495084118.USD","BK0188","LU0405327148.USD","LU1064131003.USD","BK0028","LU2097828631.EUR","BK0239","LU1064130708.USD","LU0359201612.USD","LU2097828474.EUR","LU2097828805.USD","BK0196","LU2289578879.USD","IBBJ","LU1969619763.USD","BK0012","LU1146622755.USD","LU0359201885.HKD","LU2543165471.USD","LU1255011170.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660118408","title":"Jiangsu Hengrui Hong Kong Shares Hit Record Low on Quarterly Profit Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2660118408","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660118408?lang=en_us&edition=fundamental","pubTime":"2026-08-20 12:20","pubTimestamp":1787199653,"startTime":"0","endTime":"0","summary":"BUZZ-Jiangsu Hengrui Hong Kong shares hit record low on quarterly profit miss** Hong Kong shares of Jiangsu Hengrui Pharmaceuticals1276.HKdrop 11.2% to HK$48.8, record low since debut in May 2025** St","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nL1N44H03J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997244956.HKD","600276","BK0028","BK0196","LU1997245177.USD","LU1997245094.SGD","LU2148510915.USD","BK0060","LU0359201612.USD","LU2097828805.USD","LU2289578879.USD","LU2543165471.USD","01276","BK0239","LU1580142542.USD","LU1328615791.USD","BK1191","LU2328871848.SGD","LU0405327494.USD","LU2580892862.HKD","LU1064131003.USD","LU0359202008.SGD","LU2097828474.EUR","BK0012","LU1969619763.USD","LU1781817850.SGD","LU2097828557.USD","LU0359201885.HKD","LU0405327148.USD","LU1655091616.SGD","LU2097828631.EUR","LU1820825898.SGD","LU1146622755.USD","LU2488822045.USD","LU2580892789.USD","LU1064130708.USD","LU2097828714.EUR","BK0188","BK0183","LU1255011170.USD","LU2495084118.USD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148990473","title":"Movement Alert｜HENGRUI PHARMA Falls 8.55% in Regular Trading, H1 Revenue Declines as Core Profit Drops 12.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148990473","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148990473?lang=en_us&edition=fundamental","pubTime":"2026-08-20 09:33","pubTimestamp":1787189623,"startTime":"0","endTime":"0","summary":"On August 20, HENGRUI PHARMA fell 8.55% in regular trading, trading at HK$50.85/share, with turnover of HK$109 million. The selloff was triggered by the company's disappointing first-half earnings...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"HENGRUI PHARMA Falls as H1 Revenue Declines as Core Profit Drops 12.7%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171904948","title":"Hengrui Pharma Announces Resignation of Joint Company Secretary Liu Xiaohan","url":"https://stock-news.laohu8.com/highlight/detail?id=1171904948","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171904948?lang=en_us&edition=fundamental","pubTime":"2026-08-19 22:29","pubTimestamp":1787149741,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”) disclosed that Ms. Liu Xiaohan resigned from her position as joint company secretary, effective 19 August 2026. According to the board,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185153566","title":"Hengrui Pharma Appoints Tian Fei as New Board Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=1185153566","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185153566?lang=en_us&edition=fundamental","pubTime":"2026-08-19 22:22","pubTimestamp":1787149332,"startTime":"0","endTime":"0","summary":"Hengrui Pharma (01276) has announced a key executive change, with the appointment of Tian Fei as the company's new Board Secretary.The decision was formally ratified during the fourth meeting of the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","LU2543165471.USD","LU1997245177.USD","LU2580892789.USD","LU1064131003.USD","LU2495084118.USD","BK0188","LU1969619763.USD","BK0028","LU1146622755.USD","BK1191","LU0359201612.USD","LU1255011170.USD","LU1997244956.HKD","LU1997245094.SGD","LU2097828474.EUR","LU2488822045.USD","LU2097828631.EUR","LU2097828714.EUR","BK0060","600276","LU0405327494.USD","LU0359201885.HKD","BK0012","LU2289578879.USD","LU1328615791.USD","LU0405327148.USD","LU1820825898.SGD","LU2097828557.USD","LU2580892862.HKD","LU1781817850.SGD","LU1655091616.SGD","BK0239","LU2148510915.USD","LU0359202008.SGD","LU1580142542.USD","01276","LU2328871848.SGD","LU1064130708.USD","LU2097828805.USD","LU1023057109.AUD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139277418","title":"HENGRUI PHARMA Proposes New H-Share Incentive Scheme for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1139277418","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139277418?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:52","pubTimestamp":1787147541,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA (01276) announced that on August 19, 2026, its board has resolved to recommend the adoption of the 2026 H-Share Share Plan.The plan will take effect upon approval at the upcoming first extraordinary general meeting of the company in 2026.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","LU2580892789.USD","LU2097828805.USD","LU2543165471.USD","LU1328615791.USD","BK0028","LU1655091616.SGD","LU2328871848.SGD","LU2097828631.EUR","LU2495084118.USD","LU2580892862.HKD","LU1781817850.SGD","LU1580142542.USD","600276","01276","LU1023057109.AUD","LU1997244956.HKD","LU2289578879.USD","BK0183","LU2148510915.USD","BK0239","BK0012","LU1997245177.USD","BK0060","LU0359201612.USD","LU1064130708.USD","LU1969619763.USD","LU1997245094.SGD","LU1146622755.USD","LU2097828714.EUR","LU0405327494.USD","LU2097828474.EUR","LU1255011170.USD","LU0359201885.HKD","BK0188","LU0405327148.USD","LU1820825898.SGD","BK0196","LU0359202008.SGD","LU2488822045.USD","BK1191","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196895712","title":"Hengrui Pharma Maintains H1 2026 Profitability; Innovative Drug Sales Rise 16.4% Despite Flat Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=1196895712","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196895712?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:46","pubTimestamp":1787147187,"startTime":"0","endTime":"0","summary":"Hengrui Pharma reported first-half 2026 revenue of RMB 15.46 billion, edging down 1.9% year on year as lower licensing receipts offset higher product sales. Gross profit slipped 2.2% to RMB 13.34...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Hengrui Pharma Maintains H1 2026 Profitability; Innovative Drug Sales Rise 16.4% Despite Flat Revenue","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100417660","title":"Hengrui Pharma Unveils 2026 A-Share Employee Stock Ownership Plan Valued at Approx. RMB 0.34 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1100417660","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100417660?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:46","pubTimestamp":1787147163,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) has approved a new 2026 A-share Employee Stock Ownership Scheme (ESOS), pending shareholder approval at an upcoming extraordinary general...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}